Bausch Health Spinoff Sends Stock Higher

The company also disclosed a $2.76 billion revenue jump

Digital Content Manager
Jan 14, 2022 at 10:14 AM
facebook twitter linkedin

Bausch Health Companies Inc (NYSE:BHC) just said that its eye-care products unit Bausch + Lomb filed to go public on Thursday on both U.S. and Canadian exchanges via an initial public offering (IPO). Bausch Health also disclosed a $2.76 billion jump in revenue in the last nine months ended on Sept. 30, 2021. At last check, BHC was up 2.4% at $27.40. 

After a brief break below the trendline, it looks like Bausch Health stock has found support at its 320-day moving average, though a ceiling at the $28 level is still looming just above as potential pressure on the charts. The equity just recently toppled its year-over-year breakeven, sporting a slim 1.3% lead. 

While most analysts are optimistic on BHC, there's still room for upgrades. Of the seven in coverage, two consider the stock a "hold" or worse. Meanwhile, the 12-month consensus price target of $35.73 is a 33% premium to current levels. 

Options traders are likely cheering today's news. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), BHC sports a 10-day call/put volume ratio of 8.82, which stands higher than 87% of readings from the past year. This means options traders are picking up calls at a much quicker-than-usual clip recently. 


Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!